Ningbo Sanxing Medical ElectricLtd Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Ningbo Sanxing Medical ElectricLtd wird ein jährliches Gewinn- und Umsatzwachstum von 21.3% bzw. 21.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22% betragen.

Wichtige Informationen

21.3%

Wachstumsrate der Gewinne

21.0%

EPS-Wachstumsrate

Electrical Gewinnwachstum	26.2%
Wachstumsrate der Einnahmen	21.1%
Zukünftige Eigenkapitalrendite	22.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	29 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Ningbo Sanxing Medical ElectricLtd (SHSE:601567) A Risky Investment?

Nov 14

There's Been No Shortage Of Growth Recently For Ningbo Sanxing Medical ElectricLtd's (SHSE:601567) Returns On Capital

Oct 17

Does Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Deserve A Spot On Your Watchlist?

Sep 11

Ningbo Sanxing Medical Electric Co.,Ltd.'s (SHSE:601567) Business And Shares Still Trailing The Market

Aug 14

A Look At The Intrinsic Value Of Ningbo Sanxing Medical Electric Co.,Ltd. (SHSE:601567)

Jul 17

Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Might Have The Makings Of A Multi-Bagger

Jul 04

These 4 Measures Indicate That Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Is Using Debt Safely

Jun 03

Investors Shouldn't Be Too Comfortable With Ningbo Sanxing Medical ElectricLtd's (SHSE:601567) Earnings

May 02

Ningbo Sanxing Medical Electric Co.,Ltd.'s (SHSE:601567) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17

We Ran A Stock Scan For Earnings Growth And Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Passed With Ease

Mar 26

Ningbo Sanxing Medical Electric Co.,Ltd.'s (SHSE:601567) Shares Lagging The Market But So Is The Business

Feb 27

Gewinn- und Umsatzwachstumsprognosen

SHSE:601567 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	21,531	3,545	2,232	3,088	5
12/31/2025	17,771	2,871	1,484	2,695	6
12/31/2024	14,341	2,321	102	1,907	6
9/30/2024	13,558	2,230	1,727	2,637	N/A
6/30/2024	12,911	2,184	1,251	1,983	N/A
3/31/2024	12,239	1,998	1,030	1,754	N/A
12/31/2023	11,463	1,904	1,345	1,901	N/A
9/30/2023	10,535	1,736	817	1,293	N/A
6/30/2023	10,249	1,467	1,016	1,472	N/A
3/31/2023	9,364	1,053	1,384	1,789	N/A
12/31/2022	9,098	948	819	1,223	N/A
9/30/2022	8,821	724	466	897	N/A
6/30/2022	8,076	541	161	532	N/A
3/31/2022	7,617	685	-231	102	N/A
12/31/2021	7,023	690	-96	199	N/A
9/30/2021	6,706	893	380	615	N/A
6/30/2021	6,949	958	501	711	N/A
3/31/2021	7,100	919	905	1,111	N/A
12/31/2020	7,093	956	1,024	1,231	N/A
9/30/2020	7,368	968	862	1,067	N/A
6/30/2020	7,187	956	839	1,068	N/A
3/31/2020	6,840	986	784	1,068	N/A
12/31/2019	6,805	1,004	694	972	N/A
9/30/2019	6,588	860	153	424	N/A
6/30/2019	6,392	844	199	494	N/A
3/31/2019	6,064	634	120	384	N/A
12/31/2018	5,870	508	128	445	N/A
9/30/2018	6,109	887	455	741	N/A
6/30/2018	5,950	869	N/A	879	N/A
3/31/2018	5,595	893	N/A	922	N/A
12/31/2017	5,368	891	N/A	934	N/A
9/30/2017	5,235	853	N/A	1,222	N/A
6/30/2017	5,016	822	N/A	1,000	N/A
3/31/2017	5,054	824	N/A	981	N/A
12/31/2016	4,922	794	N/A	882	N/A
9/30/2016	4,629	594	N/A	473	N/A
6/30/2016	4,453	572	N/A	569	N/A
3/31/2016	4,301	589	N/A	540	N/A
12/31/2015	4,158	564	N/A	541	N/A
9/30/2015	3,806	508	N/A	578	N/A
6/30/2015	3,736	492	N/A	641	N/A
3/31/2015	3,542	418	N/A	417	N/A
12/31/2014	3,310	407	N/A	400	N/A
9/30/2014	2,895	349	N/A	190	N/A
6/30/2014	2,467	308	N/A	83	N/A
3/31/2014	2,199	284	N/A	202	N/A
12/31/2013	2,247	282	N/A	270	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 601567Das prognostizierte Gewinnwachstum (21.3% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 601567Die Erträge des Unternehmens (21.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26% pro Jahr).

Hohe Wachstumserträge: 601567Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 601567Die Einnahmen des Unternehmens (21.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 601567Die Einnahmen des Unternehmens (21.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 601567Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22%)

Ningbo Sanxing Medical ElectricLtd Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 24% to CN¥28.00

Recent updates

Is Ningbo Sanxing Medical ElectricLtd (SHSE:601567) A Risky Investment?

Third quarter 2024 earnings released: EPS: CN¥0.48 (vs CN¥0.43 in 3Q 2023)

There's Been No Shortage Of Growth Recently For Ningbo Sanxing Medical ElectricLtd's (SHSE:601567) Returns On Capital

Now 21% undervalued

Ningbo Sanxing Medical Electric Co.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Now 21% undervalued after recent price drop

Does Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Deserve A Spot On Your Watchlist?

Now 21% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: CN¥0.55 (vs CN¥0.43 in 2Q 2023)

Ningbo Sanxing Medical Electric Co.,Ltd.'s (SHSE:601567) Business And Shares Still Trailing The Market

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Ningbo Sanxing Medical Electric Co.,Ltd. (SHSE:601567)

Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Might Have The Makings Of A Multi-Bagger

Ningbo Sanxing Medical Electric Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

These 4 Measures Indicate That Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Is Using Debt Safely

Investors Shouldn't Be Too Comfortable With Ningbo Sanxing Medical ElectricLtd's (SHSE:601567) Earnings

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.19 in 1Q 2023)

Ningbo Sanxing Medical Electric Co.,Ltd., Annual General Meeting, May 17, 2024

Ningbo Sanxing Medical Electric Co.,Ltd.'s (SHSE:601567) Shares Climb 25% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 16%

Ningbo Sanxing Medical Electric Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

We Ran A Stock Scan For Earnings Growth And Ningbo Sanxing Medical ElectricLtd (SHSE:601567) Passed With Ease

Now 21% undervalued

Investor sentiment improves as stock rises 16%

Ningbo Sanxing Medical Electric Co.,Ltd.'s (SHSE:601567) Shares Lagging The Market But So Is The Business

Price target increased by 24% to CN¥28.00

Ningbo Sanxing Medical Electric Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Ningbo Sanxing Medical Electric Co.,Ltd. (SHSE:601567) announces an Equity Buyback for CNY 300 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.25 in 3Q 2022)

Ningbo Sanxing Medical Electric Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.13 in 2Q 2022)

Investor sentiment improves as stock rises 17%

Ningbo Sanxing Medical Electric Co.,Ltd. to Report First Half, 2023 Results on Aug 24, 2023

Ningbo Sanxing Medical Electric Co.,Ltd. agreed to acquire Yuyao Mingzhou Rehabilitation Hospital Co., Ltd. from Ningbo Aux Rehabilitation Medical Investment Management Co., Ltd. for CNY 110 million.

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.12 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.24 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.21 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.69 (vs CN¥0.75 in FY 2019)

New 90-day low: CN¥6.05

New 90-day low: CN¥6.40

Third quarter earnings released

Ningbo Sanxing Medical Electric Co.,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥6.66

Ningbo Sanxing Medical Electric Co.,Ltd. (SHSE:601567) completed the acquisition of 60% stake in FOXYTECH Sp. z o.o from Sonel S.A. (WSE:SON).

New 90-day high - CN¥7.89

Earnings released

Ningbo Sanxing Medical Electric Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken